Maissaa Janbain
Tulane University
H-index: 9
North America-United States
Top articles of Maissaa Janbain
Multicenter evaluation of the haemostatic activity of emicizumab in patients with severe haemophilia A
Journal of Thrombosis and Haemostasis
2024/4/6
Maissaa Janbain
H-Index: 7
Yesim Dargaud
H-Index: 19
Bleeding control with emicizumab in patients with acquired hemophilia a
The American Journal of the Medical Sciences
2024/2/1
Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A
European Journal of Haematology
2024/2
Maissaa Janbain
H-Index: 7
Johannes Oldenburg
H-Index: 48
Protein S antibody as an adjunct therapy for hemophilia B
Blood Advances
2024/1/23
Narender Kumar
H-Index: 9
Sabyasachi Chatterjee
H-Index: 10
Maissaa Janbain
H-Index: 7
Rinku Majumder
H-Index: 5
An in Vitro Pilot Study of the Role of Factor IX As an Alternative to Bypassing Agents in the Treatment of Breakthrough Bleeds in Patients with Hemophilia a and Inhibitors …
Blood
2023/11/28
Maissaa Janbain
H-Index: 7
Yesim Dargaud
H-Index: 19
Multicenter Evaluation of the Hemostatic Activity of Emicizumab in Patients with Severe Hemophilia a Using Thrombin Generation Assay
Blood
2023/11/28
Maissaa Janbain
H-Index: 7
Real‐world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non‐interventional, post‐authorization safety study
Haemophilia
2023/9
Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A
Hämostaseologie
2023/2
Managing Pregnant Women with Hemophilia and von Willebrand Disease: How Do We Provide Optimum Care and Prevent Complications?
2022/12/31
Maissaa Janbain
H-Index: 7
EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study
Value in Health
2022/12/1
Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days …
Blood
2022/11/15
Maissaa Janbain
H-Index: 7
Johannes Oldenburg
H-Index: 48
Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
Blood
2022/11/15
Cardiovascular Disease Prevention in Persons with Hemophilia
Blood
2022/11/15
Maissaa Janbain
H-Index: 7
Clinical utility of subcutaneous factor VIII replacement therapies in hemophilia A: a review of the evidence
2021/12/7
Emicizumab for the treatment of acquired hemophilia A: a multicenter US case series
Haemophilia
2023/1
Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study
Haemophilia
2021/11
Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A
BMJ open
2021/9/1
Maissaa Janbain
H-Index: 7
Johannes Oldenburg
H-Index: 48
First interim analysis from the observational hempowr study evaluating effectiveness and safety of real-world treatment with damoctocog alfa pegol in previously treated …
Research and Practice in Thrombosis and Haemostasis
2021
Protocol: Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A
BMJ Open
2021
Maissaa Janbain
H-Index: 7
Johannes Oldenburg
H-Index: 48
Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study
Journal of Thrombosis and Haemostasis
2020/3/1
